Cardiac natriuretic peptides: Hormones with anticancer effects that localize to nucleus, cytoplasm, endothelium, and fibroblasts of human cancers

Histology and Histopathology

Volumn 21, Issue 7-9, 2006, Pages 775-783

  Saba, S R ^a   Vesely, David K ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer; DNA synthesis; Natriuretic peptides; Nucleus

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; GROWTH PROMOTOR; HORMONE PRECURSOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONG ACTING DRUG; LONG ACTING NATRIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEPTIDE ANTIBODY; PEPTIDE HORMONE; PLACEBO; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CELL NUCLEUS; CYTOPLASM; DNA SYNTHESIS; ENDOTHELIUM; FIBROBLAST; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; KIDNEY; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; ENDOTHELIUM CELL; FEMALE; MALE; METABOLISM; MOUSE; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ATRIAL NATRIURETIC FACTOR; CELL NUCLEUS; CYTOPLASM; DNA; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; MALE; MICE;

EID: 33645774369     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Ackerman B.H., Overton R.M., McCormick M.T., Schocken D.D. and Vesely D.L. (1997). Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans after a one-hour infusion. J. Pharmacol. Exp. Therap. 282, 603-608.
2. Barr C.S., Rhodes P. and Struthers A.D. (1996). C-type natriuretic peptide. Peptides 17, 1243-1251.
3. Benjamin B.A. and Peterson T.V. (1995). Effects of proANF-(31-67) on sodium excretion in conscious monkeys. Am. J. Physiol. 269, R1351-R1355.
4. Brenner B.M., Ballermann B.J., Gunning M.E. and Zeidel M.L. (1990). Diverse biological actions of atrial natriuretic peptide. Physiol. Rev. 70, 665-699.
5. Burack W.R. and Shaw A.S. (2000). Signal transduction: hanging on a scaffold. Curr. Opin. Cell Biol. 12, 211-216.
6. Burwen S.J. and Jones A.L. (1987). The association of polypeptide hormones and growth factors with nuclei of target cells. Trends Biochem. Sci. 12, 159-162.
7. +-ATPase of the atrial natriuretic peptides. Endocrinology 136, 2033-2039.
8. Clark L.C., Farghaly H., Saba S.R. and Vesely D.L. (2000). Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days. Am. J. Physiol. 278, H1555-H1564.
9. De Palo E.F., Woloszczuk W., Meneghetti M., DePalo C.B., Nielsen H.B. and Secher N.H. (2000). Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin. Chem 46, 843-847.
10. Dietz J.R., Scott D.Y., Landon C.S. and Nazian S.J. (2001). Evidence supporting a physiological role for pro ANP (1-30) in the regulation of renal excretion. Am. J. Physiol. 280, R1510-R1517.
11. Dietz J.R., Vesely D.L., Gower W.R. Jr. and Nazian S.J. (1995). Secretion and renal effects of ANF prohormone peptides. Clin. Exp. Pharmacol. Physiol. 22, 115-120.
12. Flynn T.G. (1996). Past and current perspectives on the natriuretic peptides. Proc. Soc. Exp. Biol. Med. 213, 98-104.
13. Franz M., Woloszczuk W. and Horl W.H. (2000). N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int. 58, 374-378.
14. Franz M., Woloszczuk W. and Horl W.H. (2001). Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int. 59, 1928-1934.
15. Gardner D.G., Deschepper C.T., Ganong W.F., Hane S., Fiddes J., Baxter J.D. and Lewicki J. (1986). Extra-atrial expression of the gene for atrial natriuretic factor. Proc. Natl. Acad. Sci. USA 83, 6697-6701.
16. Gardner D.G., Kovacic-Milivojevic B.K. and Garmai M. (1997). Molecular biology of the natriuretic peptides. In: Atrial natriuretic peptides. Vesely D.L. (ed). Research Signpost. Trivandrum, India. pp 15-38.
17. Gower W.R. Jr., San Miguel G.I., Carter G.M., Hassan I., Farese R.V. and Vesely D.L. (2003). Enhanced atrial natriuretic prohormone gene expression in cardiac and extracardiac tissues of type II diabetic Goto-Kakizaki rat. Mol. Cell Biochem. 252, 263-271.
18. Gower W.R. Jr., Vesely B.A., Alli A.A. and Vesely D.L. (2005). Four peptides decrease human colon adenocarcinoma. Cell number and DNA synthesis via cyclic GMP. Int. J. Gastrointest. Cancer 36 (in press).
19. 2. J. Clin. Invest. 89, 1411-1417.
20. Gunning M.E. and Brenner B.M. (1992). Natriuretic peptides and the kidney: current concepts. Kidney Int. 42(Supp 38), S127-S133.
21. Habibullah A.A., Villarreal D., Freeman R.H., Dietz J.R., Vesely D.L. and Simmons J.C. (1995). Atrial natriuretic peptide fragments in dogs with experimental heart failure. Clin. Exp. Pharmacol. Physiol. 22, 130-135.
22. Hirata Y., Takata S., Tomita M. and Takaichi S. (1985). Binding internalization and degradation of atrial natriuretic peptide in cultured smooth muscle cells of rat. Biochem. Biophys. Res. Commun. 132 976-984.
23. Hughes R.J., Struther R.S., Fong A.M. and Insel P.A. (1987). Regulation of the atrial natriuretic peptide receptor on a smooth muscle cell Am. J. Physiol. 253, C809-C816.
24. Hunter E.F.M., Kelly P.A., Prowse C., Woods F.J. and Lowry PJ. (1998) Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scan. J. Clin. Lab. Invest. 58, 205-216.
25. Kawano H., Do Y.S., Kawano Y., Starnes V., Barr M., Law R.E. and Hsueh W.A. (2000). Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101, 1130-1137.
26. Lainchbury J., Richards A.M. and Nicholls M.G. (1997). Brain natriuretic peptide in heart failure. In: Atrial natriuretic peptides. Vesely D.L. (ed). Research Signpost. Trivandrum, India. pp 151-158.
27. Lang C.C., Choy A.M., Henderson I.S., Coutie W.J. and Struthers A.D. (1992). Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin. Sci. 82, 127-131.
28. Levin E.R., Gardner D.G. and Samson W.K. (1998). Natriuretic peptides. N. Engl. J. Med. 339, 321-328.
29. Maack T., Marion D.N., Camargo M.J., Kleinert H.D., Laragh J.H., Vaughan E.D. Jr. and Atlas S.A. (1984). Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs. Am. J. Med. 77, 1069-1075.
30. 2-terminus are natriuretic and/or kaliuretic. Am. J. Physiol. 258, F1401-F1408.
31. Mohapatra S.S., Lockey R.F., Vesely D.L. and Gower W.R. Jr. (2004). Natriuretic peptides and genesis of asthma: An emerging paradigm? J. Allergy Clinical Immuol. 114, 520-526.
32. Morel G. and Heisler S. (1988). Internalization of endogenous and exogenous atrial natriuretic peptide by target issues. Electr. Microsc. Rev. 1, 221-231.
33. Napier MA., Arcuri K.E. and Vandlen R.L. (1986). Binding and internalization of atrial natriuretic factor by high-affinity receptors in A10 smooth muscle cells. Arch. Biochem. Biophys. 248, 516-522.
34. Nasser A., Dietz J.R., Siddique M., Patel H., Khan N., Antwi E.K., San Miguel G.I., McCormick M.T., Schocken D.D. and Vesely D.L. (2001). Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. Am. J. Cardiol. 88, 23-29.
35. Ogawa Y., Itoh H. and Nakao K. (1995). Molecular biology and biochemistry of natriuretic peptide family. Clin. Exp. Pharmacol. Physiol. 22, 49-53.
36. Pitchumoni C.S. (1998). Pancreatic disease. In: Internal Medicine. Stein J.H. (ed). Mosby. St. Louis. pp 2233-2247.
37. Poulos J.E., Gower W.R. Jr., Sullebarger J.T., Fontanet H.L. and Vesely D.L. (1996). Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide gene expression. Cardiovasc. Res. 32, 909-919.
38. Ramirez G., Saba S.R., Dietz J.R. and Vesely D.L. (1992). Immunocytochemical localization of proANF1-30, proANF 31-67, and atrial natriuretic factor in the kidney. Kidney Int. 41, 334-341.
39. Rosenzweig A. and Seidman C.E. (1991). Atrial natriuretic factor and related peptide hormones. Annu. Rev. Biochem. 60, 229-255.
40. Ruskoaho H. (1992). Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol. Rev. 44, 479-602.
41. Saba S.R., Ramirez G. and Vesely D.L. (1993). Immunocytochemical localization of ProANF 1-30, ProANF 31-67, atrial natriuretic factor and urodilatin in the human kidney. Am. J. Nephrol. 13, 85-93.
42. Saba S.R., Garces A.H., Clark L.C., Soto J., Gower W.R. Jr. and Vesely D.L. (2005). Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long acting natriuretic peptide and kaliuretic peptide in human pancreatic adenocarcinomas. J. Histochem. Cytochem. 53, 989-995.
43. Shin S.J., Lee Y.J., Tan M.S., Hsieh T.J. and Tsai J.H. (1997). Increased atrial natriuretic peptide mRNA expression in the kidney of diabetic rats. Kidney Int. 51, 1100-1105.
44. Totsune K., Mackenzie H.S., Totsune H., Troy J.L., Lytton J. and Brenner B.M. (1998). Upregulation of atrial natriuretic peptide gene expression in remnant kidney of rats with reduced renal mass. J. Am. Soc. Nephrol. 9, 1613-1617.
45. Vesely B.A., McAfee Q., Gower W.R. Jr. and Vesely D.L. (2003). Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur. J. Clin. Invest. 33, 998-1005.
46. Vesely B.A., Alli A.A., Song S., Gower W.R. Jr., Sanchez-Ramos J. and Vesely D.L. (2005a). Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur. J. Clin. Invest. 35, 700-710.
47. Vesely B.A., Song S., Sanchez-Ramos J., Fitz S.R., Alli A., Solivan S.R., Gower W.R. Jr. and Vesely D.L. (2005b). Five cardiac hormones decrease the number of human small-cell cancer cells. Eur. J. Clin. Invest. 35, 399-398.
48. Vesely B.A., Song S., Sanchez-Ramos J., Fitz S.R., Solivan S.M., Gower W.R. Jr. and Vesely D.L. (2005c). Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur. J. Clin. Invest. 35, 60-69.
49. Vesely B.A., Fitz S.R., Gower W.R. Jr. and Vesely D.L. (2006). Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett. 232, 226-232.
50. Vesely D.L. (1992). Atrial natriuretic hormones. Prentice Hall. Englewood Cliffs, N.J.
51. Vesely D.L. (2001). Atrial natriuretic peptides in pathophysiological diseases. Cardiovasc. Res. 51, 647-658.
52. Vesely D.L. (2002). Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 53, 153-159.
53. Vesely D.L. (2003). Natriuretic peptides and acute renal failure. Am. J. Physiol. 285, F167-F177.
54. Vesely D.L., Norris J.S., Walters J.M., Jespersen R.R. and Baeyens D.A. (1987). Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem. Biophys. Res. Commun. 148, 1540-1548.
55. Vesely D.L., Norsk P., Winters C.J., Rico D.M., Sallman A.L. and Epstein M. (1989). Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc. Soc. Exp. Biol. Med. 192, 230-235.
56. Vesely D.L., Cornett L.E., McCleod S.L., Nash A.A. and Norris J.S. (1990). Specific binding sites for prohormones atrial natriuretic peptides 1-30, 31-67, and 99-126. Peptides 11, 193-197.
57. Vesely D.L., Dietz J.R., Parks J.R., Baig M., McCormick M.T., Cintron G. and Schocken D.D. (1998). Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 98, 323-329.
58. Vesely D.L., Douglass M.A., Dietz J.R., Giordano A.T., McCormick M.T., Rodriguez-Paz G. and Schocken D.D. (1994a). Negative feedback of atrial natriuretic peptides. J. Clin. Endocrinol. Metab. 78, 1128-1134.
59. Vesely D.L., Douglass M.A., Dietz J.R., Gower W.R. Jr., McCormick M.T., Rodriguez-Paz G. and Schocken D.D. (1994b). Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90, 1129-1140.
60. Vesely D.L., Dietz J.R., Parks J.R., Antwi E.A., Overton R.M., McCormick M.T., Cintron G. and Schocken D.D. (1999). Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure. Am. Heart J. 138, 625-632.
61. Vesely D.L., Palmer P.A. and Giordano A.T. (1992a). Atrial natriuretic factor prohormone peptides are present in a variety of tissues. Peptides 13, 165-170.
62. Vesely D.L., Sallman A.L. and Bayliss J.M. (1992b). Specific binding sites for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes. Renal Physiol. Biochem. 15, 23-32.
63. Vesely D.L., Clark L.C., Garces A.H., McAfee Q.W., Soto J. and Gower W.R. Jr. (2004). Novel therapeutic approach for cancer using four cardiovascular hormones. Eur. J. Clin. Invest. 34, 674-682.
64. Villarreal D., Reams G.P., Taraben A. and Freeman R.H. (1999). Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc. Soc. Exp. Biol. Med. 221, 166-170.
65. Vuolteenaho O., Leskinen H., Magga J., Taskinen P., Mantymaa P., Leppaluoto J. and Ruskoaho H. (1997). Regulation of atrial natriuretic peptide synthesis and secretion. In: Atrial natriuretic peptides. Vesely D.L. (ed). Research Signpost. Trivandrum, India. pp 39-52.
66. Winters C.J., Sallman A.L., Baker B.J., Meadows J., Rico D.M. and Vesely D.L. (1989). The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 80, 438-449.
67. Wolff R.A., Abbruzzese J.L. and Evans D.B. (2000). Neoplasms of the exocrine pancreas. In: Cancer medicine. Holland J.F. and Frei E. III (eds). B.C. Decker Inc. London. pp 1436-1464.
68. + reabsorption by ANP 31-67. Clin. Exp. Pharmacol. Physiol. 22, 121-124.